{
    "score": [
        1.0
    ],
    "extracted": [
        6
    ],
    "abstract": [
        "portola pharmaceuticals cut to strong sell at bidaskclub ."
    ],
    "id": "1145734.train",
    "article": [
        "portola pharmaceuticals was downgraded by stock analysts at bidaskclub from a `` sell '' rating to a `` strong sell '' rating in a report issued on friday . ptla has been the topic of several other research reports . oppenheimer set a $ 80.00 price objective on portola pharmaceuticals and gave the stock a `` buy '' rating in a report on friday , october 6th . goldman sachs group initiated coverage on portola pharmaceuticals in a report on friday , december 1st . they set a `` buy '' rating and a $ 75.00 price objective on the stock . ",
        "morgan stanley reaffirmed an `` overweight '' rating and set a $ 81.00 price objective on shares of portola pharmaceuticals in a report on friday , october 6th . zacks investment research downgraded portola pharmaceuticals from a `` hold '' rating to a `` sell '' rating in a report on thursday , january 4th . finally , william blair reaffirmed a `` buy '' rating on shares of portola pharmaceuticals in a report on monday , january 1st . one equities research analyst has rated the stock with a sell rating , two have assigned a hold rating and nine have assigned a buy rating to the company 's stock . ",
        "the company currently has an average rating of `` buy '' and a consensus target price of $ 70.65 . portola pharmaceuticals opened at $ 49.63 on friday . the company has a market capitalization of $ 3,240.00 , a p/e ratio of -11.49 and a beta of 1.21 . the company has a quick ratio of 8.31 , a current ratio of 8.31 and a debt-to-equity ratio of 0.24 . portola pharmaceuticals has a 1-year low of $ 24.53 and a 1-year high of $ 67.10 . portola pharmaceuticals last announced its earnings results on monday , november 6th . ",
        "the biopharmaceutical company reported eps for the quarter , topping the consensus estimate of by $ 0.08 . the business had revenue of $ 3.83 million for the quarter , compared to the consensus estimate of $ 4.71 million . portola pharmaceuticals had a negative return on equity of 110.46 % and a negative net margin of 938.19 % . portola pharmaceuticals 's revenue was down 58.9 % compared to the same quarter last year . during the same period in the previous year , the business earned eps . research analysts anticipate that portola pharmaceuticals will post -4.94 earnings per share for the current fiscal year . ",
        "in other portola pharmaceuticals news , director henry ward wolff sold 12,000 shares of the company 's stock in a transaction on friday , december 15th . the stock was sold at an average price of $ 47.00 , for a total transaction of $ 564,000.00 . the transaction was disclosed in a filing with the sec , which is available at this link . 5.50 % of the stock is currently owned by corporate insiders . institutional investors have recently modified their holdings of the business . zurcher kantonalbank zurich cantonalbank raised its position in shares of portola pharmaceuticals by 14.2 % during the 2nd quarter . ",
        "zurcher kantonalbank zurich cantonalbank now owns 2,078 shares of the biopharmaceutical company 's stock valued at $ 117,000 after acquiring an additional 258 shares during the last quarter . qs investors llc bought a new stake in shares of portola pharmaceuticals during the 2nd quarter valued at $ 147,000 . oppenheimer asset management inc. . raised its position in shares of portola pharmaceuticals by 251.2 % during the 3rd quarter . oppenheimer asset management inc. . now owns 2,862 shares of the biopharmaceutical company 's stock valued at $ 155,000 after acquiring an additional 2,047 shares during the last quarter . ",
        "canada pension plan investment board bought a new stake in shares of portola pharmaceuticals during the 3rd quarter valued at $ 178,000 . finally , wealthplan partners llc raised its position in shares of portola pharmaceuticals by 2,781.5 % during the 2nd quarter . wealthplan partners llc now owns 3,746 shares of the biopharmaceutical company 's stock valued at $ 210,000 after acquiring an additional 3,616 shares during the last quarter . institutional investors own 87.25 % of the company 's stock . copyright violation notice : `` portola pharmaceuticals cut to strong sell at bidaskclub '' was reported by daily political and is the sole property of of daily political . ",
        "if you are reading this story on another website , it was illegally stolen and republished in violation of us and international trademark & copyright laws . the correct version of this story can be read at pharmaceuticals company profileportola pharmaceuticals , inc is a biopharmaceutical company . the company is focused on the development and commercialization of therapeutics in the areas of thrombosis , other hematologic disorders and inflammation for patients having limited or no approved treatment options . the company 's two lead programs , betrixaban and andexanet alfa , address unmet medical needs in the area of thrombosis , or blood clots . "
    ]
}